A rumored takeover candidate is among the five small-cap biotech stocks trading under $10 highlighted in today’s article, all of which boast Buy ratings from well-known Wall Street firms – and solid upside potential. For these five biotech stocks, which are suited for very aggressive investors, CLICK HERE.
In January, the small-cap biotech highlighted in today’s article received FDA approval for its treatment for childhood peanut allergy – and with peanut allergy being the most common food allergy in the U.S. (with cases of the condition rising rapidly) and the fact that this is currently the only FDA-approved treatment for the condition (thanks to a competitor encountering some…
When it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors…
Each of these three small-cap biotech stocks surged more than 100% last week. The author of today’s article notes that “It isn’t unusual to see small-cap biotechs with nine-figure market caps continue to make further gains, but they don’t always continue rising.” So which of these three small-cap biotechs might be at the beginning of a much larger move higher?…